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Clinical PerspectiveWhat Is New?Our findings suggest that factors not related to the conduit patency, such as the patients' general status or quality of the target vessels, play a role in determining the outcome of observational studies and that a selection bias is present even in propensity‐score--matched analyses.What Are the Clinical Implications?Our findings elicit concerns regarding the ability of the propensity‐matching process to overcome selection bias and assure comparability between groups.The long‐term clinical outcomes data from the ART (Arterial Revascularization Trial) trial and new randomized studies are needed to clarify the effect of bilateral internal thoracic artery grafting in patients undergoing coronary bypass surgery.

 {#jah32844-sec-0008}

A clear contradiction between observational and randomized studies exists in the literature on the effect of multiple internal thoracic artery grafts in patients undergoing coronary artery bypass surgery.

In the 1980s, it was recognized that in coronary artery bypass surgery patients long‐term survival was enhanced when the left anterior descending (LAD) was grafted with a left internal thoracic artery, rather than a saphenous vein graft (SVG).[1](#jah32844-bib-0001){ref-type="ref"} By extension, the use of bilateral internal thoracic arteries (BITAs) should further increase postoperative survival, compared with the use of a single internal thoracic artery (SITA).[2](#jah32844-bib-0002){ref-type="ref"} This difference is generally attributed to greater and more‐durable patency of the internal thoracic artery compared with the SVG, as well as increased late SVG atherosclerosis.[3](#jah32844-bib-0003){ref-type="ref"}

In the past 25 years, a very large amount of observational data, including 6 meta‐analyses,[4](#jah32844-bib-0004){ref-type="ref"}, [5](#jah32844-bib-0005){ref-type="ref"}, [6](#jah32844-bib-0006){ref-type="ref"}, [7](#jah32844-bib-0007){ref-type="ref"}, [8](#jah32844-bib-0008){ref-type="ref"}, [9](#jah32844-bib-0009){ref-type="ref"} have supported this concept. On this basis, the use of BITA is a class IIA recommendation in patients with a long anticipated life expectancy by current guidelines and professional society position papers.[10](#jah32844-bib-0010){ref-type="ref"}, [11](#jah32844-bib-0011){ref-type="ref"}, [12](#jah32844-bib-0012){ref-type="ref"}

The randomized studies, however, reported different results. To date, there have been 4 randomized controlled trials (RCTs) comparing BITA and SITA.[13](#jah32844-bib-0013){ref-type="ref"}, [14](#jah32844-bib-0014){ref-type="ref"}, [15](#jah32844-bib-0015){ref-type="ref"}, [16](#jah32844-bib-0016){ref-type="ref"} In these studies, survival has been similar following BITA and SITA grafting. In the largest of the RCTs, the ART (Arterial Revascularization Trial), mortality was 8.7% after BITA grafting and 8.4% following SITA at 5 years.[16](#jah32844-bib-0016){ref-type="ref"}

There are several possible explanations for the discrepant findings between observational and RCT evidence. The RCTs may not have sufficient sample size or follow‐up to detect a mortality difference compared with observational series. In the ART trial, a relatively higher proportion of crossovers in the patients randomized to BITA, as well as the allowed use of a radial artery in the SITA group, may have diluted the treatment effect.

The other possible explanation, however, is that the benefit observed in the observational studies for BITA grafting is largely related to unmeasured confounders.

The objective of this study is to perform a meta‐analysis of the observational literature comparing survival following BITA and SITA grafting. To evaluate whether unmeasured confounders rather than biological superiority explained the BITA effect, we chose to compare both 1‐year as well as late survival in the BITA and SITA cohorts. We postulated that BITA would not affect 1‐year survival based on the natural history of SVG occlusion. The latter analysis was restricted to propensity‐score--matched studies, because PSM is considered the best method to minimize confounding in observational series.

Methods {#jah32844-sec-0009}
=======

The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Search Strategy and Study Selection {#jah32844-sec-0010}
-----------------------------------

This systematic review was conducted in accord to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines.[17](#jah32844-bib-0017){ref-type="ref"}

Pubmed and OVID\'s version of MEDLINE was searched from January 1972 to August 2017 for publications comparing BITA versus SITA grafting on all‐cause mortality. The following keywords were combined with the Boolean operator "or": "bilateral internal mammary," "bilateral internal thoracic," "total arterial revascularization," and "multiple arterial revascularization." The full search strategy can be found in Data [S1](#jah32844-sup-0001){ref-type="supplementary-material"}. All citations were screened for study inclusion independently by 2 investigators (A.D.F. and M.G.). Any disagreements were discussed and resolved by consensus. In addition, the bibliography of all studies and meta‐analyses was searched to identify further publications.

Inclusion criteria for analysis were: Observational study (unadjusted and adjusted studies were eligible).Sample size of at least 100 patients in each group.Follow‐up duration longer than 30 days.Written in English language.

We excluded studies that were: RCTs, not performed in humans, review articles, case reports, editorials, and expert opinions. To ensure that the analysis was strictly limited to a comparison of BITA versus SITA, we excluded studies where an additional arterial graft was used in 1 of the 2 groups and it was not possible to abstract the exact information for the isolated BITA and SITA series. In case of overlapping between studies or multiple publications from the same center, only the publication with the largest sample size was considered.

The quality of included studies was assessed using the Newcastle--Ottawa Scale for observational studies by 2 investigators independently (A.D.F. and M.G.).[18](#jah32844-bib-0018){ref-type="ref"} The highest possible score is 9 stars; \<6 stars was considered low quality whereas ≥6 stars was considered high quality.

Data Abstraction {#jah32844-sec-0011}
----------------

Two investigators (A.D.F. and M.G.) independently abstracted the following: study demographics (study period, country, and centers involved, sample size), study design methods, completeness of follow‐up, and follow‐up duration. In addition, the following patient characteristics in the unmatched and matched groups were also obtained: age, female sex, diabetes mellitus, left ventricular ejection fraction, and chronic obstructive pulmonary disease. Continuous variables were expressed as median (25th, 75th percentile) or as mean±SD. Categorical variables are reported as frequency (%).

For all‐cause mortality, crude event rates, unadjusted and adjusted hazard ratios (HRs) for BITA versus SITA grafting, and their respective 95% confidence intervals (CIs) and log *P*‐rank values were abstracted.

Outcome Analyses {#jah32844-sec-0012}
----------------

The primary outcome was all‐cause mortality. Long‐term all‐cause mortality for BITA and SITA patients was compared in all the studies.

Subgroup analyses for the primary outcome were performed as follows: Studies in the general population versus studies in specific subgroups of patients (ie, diabetics, elderly patients as defined by the individual studies, patients with renal failure, urgent/emergent cases, and patients with low ejection fraction).Unadjusted versus adjusted studies (including regression‐adjusted and PSM) in the general population.Regression‐adjusted versus PSM studies in the general population.

To assess for possible treatment allocation bias in the observational studies, we chose to compare 1‐year mortality between matched treatment groups. The 1‐year interval was chosen because the patency rate of SVGs at 1 year remains high and a survival difference related to difference in patency between arterial and venous conduits is unlikely.[19](#jah32844-bib-0019){ref-type="ref"} PSM is a robust method used to balance against confounding by indication in observational studies[20](#jah32844-bib-0020){ref-type="ref"}; for this reason, we compared all‐cause mortality for BITA and SITA at 1 year in the PSM studies only.

Analytical Plan {#jah32844-sec-0013}
---------------

*Long‐term all‐cause mortality* between BITA and SITA patients was compared in all studies initially. Comparisons were then performed in the general population studies after exclusion of studies restricted to specific patient subgroups (diabetes mellitus, elderly as defined in the individual studies, renal failure, urgent/emergent, and reduced left ventricular ejection fraction) and in the individual specific patient subgroups. Next, separate comparisons were made between BITA and SITA in the unadjusted and adjusted series (covariate adjusted and PSM combined). Last, comparisons were performed in the covariate adjusted and PSM series separately.

*One‐year mortality* between BITA and SITA patients was compared in PSM studies only.

Statistical Analysis {#jah32844-sec-0014}
--------------------

The generic inverse variance method[21](#jah32844-bib-0021){ref-type="ref"} was used to pool the natural logarithm of the incident rate ratio (IRR) across studies to account for potentially different follow‐up durations between the groups. We estimated the IRR through several means depending on the available study data. When HRs were provided, we took the natural logarithm of the HR; the SE was derived from the 95% CI or log rank *P* value.[22](#jah32844-bib-0022){ref-type="ref"} When Kaplan--Meier curves were present, we estimated the number of events from the curves to calculate the IRR, as previously described.[23](#jah32844-bib-0023){ref-type="ref"} The SE was estimated from the number of events in each arm.[22](#jah32844-bib-0022){ref-type="ref"} When event rates were not readily available, they were extracted from Kaplan--Meier curves using GetData Graph Digitizer software (version 2.26; <http://getdata-graph-digitizer.com/>) according to a previously described method.[24](#jah32844-bib-0024){ref-type="ref"}

A random‐effects model was used for statistical survival pooling, computing risk estimates with 95% CIs. Funnel plots were used to assess publication bias by graphical inspection.[25](#jah32844-bib-0025){ref-type="ref"} Hypothesis testing for equivalence was set at the 2‐tailed 0.01 level. Hypothesis testing for statistical heterogeneity was set at the 2‐tailed 0.10 level and was based on the Cochran Q test, with I^2^ values of 0% to 25%, 26% to 50%, and 51% to 100% representing low, moderate, and high heterogeneity, respectively.[26](#jah32844-bib-0026){ref-type="ref"}

Metaregression analysis examining the following variables---age, sex, diabetes mellitus, and left ventricular ejection fraction---was performed. In addition, a "leave‐one‐out" analysis and a cumulative meta‐analysis were performed in all studies ordered by year of publication.

All analyses were performed using CMA software (version 3; Biostat, Englewood, NJ).

Results {#jah32844-sec-0015}
=======

Selected Studies {#jah32844-sec-0016}
----------------

From 2921 titles, 149 pertinent studies were included for full‐text review. We excluded 111 studies that did not meet inclusion criteria. Further details of the study flow are shown in Figure [S1](#jah32844-sup-0001){ref-type="supplementary-material"}. A total of 38 observational studies were selected for the quantitative analysis. Eight nonadjusted, 9 covariate‐adjusted, and 21 PSM studies were included (see Table [1](#jah32844-tbl-0001){ref-type="table-wrap"}).[27](#jah32844-bib-0027){ref-type="ref"}, [28](#jah32844-bib-0028){ref-type="ref"}, [29](#jah32844-bib-0029){ref-type="ref"}, [30](#jah32844-bib-0030){ref-type="ref"}, [31](#jah32844-bib-0031){ref-type="ref"}, [32](#jah32844-bib-0032){ref-type="ref"}, [33](#jah32844-bib-0033){ref-type="ref"}, [34](#jah32844-bib-0034){ref-type="ref"}, [35](#jah32844-bib-0035){ref-type="ref"}, [36](#jah32844-bib-0036){ref-type="ref"}, [37](#jah32844-bib-0037){ref-type="ref"}, [38](#jah32844-bib-0038){ref-type="ref"}, [39](#jah32844-bib-0039){ref-type="ref"}, [40](#jah32844-bib-0040){ref-type="ref"}, [41](#jah32844-bib-0041){ref-type="ref"}, [42](#jah32844-bib-0042){ref-type="ref"}, [43](#jah32844-bib-0043){ref-type="ref"}, [44](#jah32844-bib-0044){ref-type="ref"}, [45](#jah32844-bib-0045){ref-type="ref"}, [46](#jah32844-bib-0046){ref-type="ref"}, [47](#jah32844-bib-0047){ref-type="ref"}, [48](#jah32844-bib-0048){ref-type="ref"}, [49](#jah32844-bib-0049){ref-type="ref"}, [50](#jah32844-bib-0050){ref-type="ref"}, [51](#jah32844-bib-0051){ref-type="ref"}, [52](#jah32844-bib-0052){ref-type="ref"}, [53](#jah32844-bib-0053){ref-type="ref"}, [54](#jah32844-bib-0054){ref-type="ref"}, [55](#jah32844-bib-0055){ref-type="ref"}, [56](#jah32844-bib-0056){ref-type="ref"}, [57](#jah32844-bib-0057){ref-type="ref"}, [58](#jah32844-bib-0058){ref-type="ref"}, [59](#jah32844-bib-0059){ref-type="ref"}, [60](#jah32844-bib-0060){ref-type="ref"}, [61](#jah32844-bib-0061){ref-type="ref"}, [62](#jah32844-bib-0062){ref-type="ref"}, [63](#jah32844-bib-0063){ref-type="ref"}, [64](#jah32844-bib-0064){ref-type="ref"} Twenty‐eight studies (162 989 patients) were performed in the general population, whereas 10 (11 216 patients) were performed in specific subgroups of patients (diabetics: 3 studies \[1533 patients\]; elderly: 4 studies \[6033 patients\]; renal failure patients: 1 study \[1203 patients\]; urgent/emergent cases: 1 study \[652 patients\]; and patients with low ejection fraction: 1 study \[1795 patients\]). An overview of the studies is summarized in Tables [1](#jah32844-tbl-0001){ref-type="table-wrap"} and [2](#jah32844-tbl-0002){ref-type="table-wrap"}, [27](#jah32844-bib-0027){ref-type="ref"}, [28](#jah32844-bib-0028){ref-type="ref"}, [29](#jah32844-bib-0029){ref-type="ref"}, [30](#jah32844-bib-0030){ref-type="ref"}, [31](#jah32844-bib-0031){ref-type="ref"}, [32](#jah32844-bib-0032){ref-type="ref"}, [33](#jah32844-bib-0033){ref-type="ref"}, [34](#jah32844-bib-0034){ref-type="ref"}, [35](#jah32844-bib-0035){ref-type="ref"}, [36](#jah32844-bib-0036){ref-type="ref"}, [37](#jah32844-bib-0037){ref-type="ref"}, [38](#jah32844-bib-0038){ref-type="ref"}, [39](#jah32844-bib-0039){ref-type="ref"}, [40](#jah32844-bib-0040){ref-type="ref"}, [41](#jah32844-bib-0041){ref-type="ref"}, [42](#jah32844-bib-0042){ref-type="ref"}, [43](#jah32844-bib-0043){ref-type="ref"}, [44](#jah32844-bib-0044){ref-type="ref"}, [45](#jah32844-bib-0045){ref-type="ref"}, [46](#jah32844-bib-0046){ref-type="ref"}, [47](#jah32844-bib-0047){ref-type="ref"}, [48](#jah32844-bib-0048){ref-type="ref"}, [49](#jah32844-bib-0049){ref-type="ref"}, [50](#jah32844-bib-0050){ref-type="ref"}, [51](#jah32844-bib-0051){ref-type="ref"}, [52](#jah32844-bib-0052){ref-type="ref"}, [53](#jah32844-bib-0053){ref-type="ref"}, [54](#jah32844-bib-0054){ref-type="ref"}, [55](#jah32844-bib-0055){ref-type="ref"}, [56](#jah32844-bib-0056){ref-type="ref"}, [57](#jah32844-bib-0057){ref-type="ref"}, [58](#jah32844-bib-0058){ref-type="ref"}, [59](#jah32844-bib-0059){ref-type="ref"}, [60](#jah32844-bib-0060){ref-type="ref"}, [61](#jah32844-bib-0061){ref-type="ref"}, [62](#jah32844-bib-0062){ref-type="ref"}, [63](#jah32844-bib-0063){ref-type="ref"}, [64](#jah32844-bib-0064){ref-type="ref"} (variables included for PSM are summarized in Table [S1](#jah32844-sup-0001){ref-type="supplementary-material"}).

###### 

Characteristics of the Studies Included in the Primary Analysis

  Study                                                  Year   Center                                                                                                         Study Period   Setting                                              Type of Study   Adjustment Performed
  ------------------------------------------------------ ------ -------------------------------------------------------------------------------------------------------------- -------------- ---------------------------------------------------- --------------- ------------------------------------------------------
  Ashraf[27](#jah32844-bib-0027){ref-type="ref"}         1994   Manchester Royal Infirmary, Manchester, UK                                                                     1989--1992     Isolated primary CABG                                Retrospective   NS
  Benedetto[28](#jah32844-bib-0028){ref-type="ref"}      2014   Harefield Hospital, London, UK                                                                                 2001--2013     Isolated primary CABG                                Retrospective   PSM
  Berreklouw[29](#jah32844-bib-0029){ref-type="ref"}     2001   Catharina Hospital, Eindhoven, The Netherlands                                                                 1985--1990     Isolated primary CABG                                Retrospective   MCPHR
  Bonacchi[30](#jah32844-bib-0030){ref-type="ref"}       2006   University of Florence, Italy                                                                                  1997--2003     Non‐elective CABG in unstable angina patients        Retrospective   MCPHR
  Buxton[31](#jah32844-bib-0031){ref-type="ref"}         1998   Austin and Repatriation Medical Center, University of Melbourne, Victoria, Australia                           1985--1995     Isolated primary CABG                                Retrospective   MCPHR
  Calafiore[32](#jah32844-bib-0032){ref-type="ref"}      2004   University Hospital, Torino, Italy and "G D\'Annunzio" University, Chieti, Italy                               1986--1999     Isolated primary CABG in patients \<75 years old     Retrospective   PSM
  Carrier[33](#jah32844-bib-0033){ref-type="ref"}        2009   Montreal Heart Institute, Montreal, Quebec, Canada                                                             1995--2007     Isolated primary CABG                                Retrospective   MCPHR
  Dalén[34](#jah32844-bib-0034){ref-type="ref"}          2014   Nationwide population‐based cohort study (Sweden)                                                              1997--2008     Isolated primary CABG                                Retrospective   PSM
  Danzer[35](#jah32844-bib-0035){ref-type="ref"}         2001   University Hospital, Geneva, Switzerland                                                                       1983--1989     Isolated primary CABG                                Retrospective   NA
  Dewar[36](#jah32844-bib-0036){ref-type="ref"}          1995   Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada               1984--1992     Isolated primary CABG                                Retrospective   Univariate regression
  Endo[37](#jah32844-bib-0037){ref-type="ref"}           2001   Tokyo Women\'s Medical University, Tokyo, Japan                                                                1985--1998     Isolated primary CABG                                Retrospective   MCPHR
  Gansera 2004[38](#jah32844-bib-0038){ref-type="ref"}   2004   Klinikum Bogenhausen, Munich, Germany                                                                          1997--1999     Isolated primary CABG                                Retrospective   NA
  Gansera 2017[39](#jah32844-bib-0039){ref-type="ref"}   2017   Klinikum Bogenhausen, Munich, Germany                                                                          2000--2011     Isolated CABG in diabetic patients, \<65 years old   Retrospective   PSM
  Grau[40](#jah32844-bib-0040){ref-type="ref"}           2015   The Valley Columbia Heart Center, Columbia University College of Physicians and Surgeons, Ridgewood, NJ, USA   1994--2013     Isolated CABG                                        Retrospective   PSM
  Hirotani[41](#jah32844-bib-0041){ref-type="ref"}       2003   Tokyo Saiseikai Central Hospital, Minato‐Ku, Tokyo, Japan                                                      1991--2003     Isolated primary CABG in diabetic patients           Retrospective   NA
  Itoh[42](#jah32844-bib-0042){ref-type="ref"}           2016   Saitama Medical Center, Jichi Medical University, Saitama, Japan                                               1990--2014     Isolated CABG in patients ≥75 years old              Retrospective   PSM
  Johnson[43](#jah32844-bib-0043){ref-type="ref"}        1989   Milwaukee Heart Surgery Associates, S.C., and St. Mary\'s Hospital, Milwaukee, WI, USA                         1972--1986     Isolated CABG                                        Retrospective   NA (patients matched with the general US population)
  Jones[44](#jah32844-bib-0044){ref-type="ref"}          2000   Baylor College of Medicine and Veterans Affairs Medical center, Houston, TX, USA                               1986--1996     Isolated primary CABG in patients \>65 years old     Retrospective   NA
  Joo[45](#jah32844-bib-0045){ref-type="ref"}            2012   Yonsei Cardiovascular Hospital, Seoul, Republic of Korea                                                       2000--2009     Isolated OPCAB                                       Retrospective   PSM
  Kelly[46](#jah32844-bib-0046){ref-type="ref"}          2012   Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada                                        1995--2007     Isolated primary CABG                                Retrospective   Non‐parsimonious MCPHR including PS quintiles
  Kieser[47](#jah32844-bib-0047){ref-type="ref"}         2011   The Province of Alberta, Canada                                                                                1995--2008     Isolated primary CABG                                Retrospective   MCPHR
  Kinoshita[48](#jah32844-bib-0048){ref-type="ref"}      2015   Shiga University of Medical Science, Otsu, Japan                                                               2002--2014     Isolated CABG‐patients stratified by GFR             Retrospective   PSM
  Kurlansky[49](#jah32844-bib-0049){ref-type="ref"}      2010   Florida Heart Research Institute, Miami, FL, USA                                                               1972--1994     Isolated CABG                                        Retrospective   PSM
  Locker[50](#jah32844-bib-0050){ref-type="ref"}         2012   Mayo Clinic, Rochester, MN, USA                                                                                1993--2009     Isolated primary CABG                                Retrospective   PSM and MCPHR
  Lytle[51](#jah32844-bib-0051){ref-type="ref"}          2004   The Cleveland Clinic Foundation, Cleveland, OH, USA                                                            1971--1989     Isolated primary CABG                                Retrospective   PSM
  Medalion[52](#jah32844-bib-0052){ref-type="ref"}       2015   Tel Aviv Sourasky Medical Center, Tel Aviv, Israel                                                             1996--2008     isolated CABG in patients ≥70 years old              Retrospective   PSM
  Mohammadi[53](#jah32844-bib-0053){ref-type="ref"}      2014   Quebec Heart and Lung Institute, Quebec City, Canada                                                           1991--2011     Isolated primary CABG in patients with EF ≤40%       Retrospective   PSM
  Nasso[54](#jah32844-bib-0054){ref-type="ref"}          2012   Multicenter                                                                                                    2003--2008     Isolated primary CABG                                Retrospective   PSM
  Naunheim[55](#jah32844-bib-0055){ref-type="ref"}       1992   St. Louis University Medical Center, St. Louis, MS, USA                                                        1972--1975     Isolated CABG                                        Retrospective   NA
  Navia[56](#jah32844-bib-0056){ref-type="ref"}          2016   Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina                                              1996--2014     Isolated CABG                                        Retrospective   PSM
  Parsa[57](#jah32844-bib-0057){ref-type="ref"}          2013   Duke University Medical Center, Durham, NC, USA                                                                1984--2009     Isolated CABG                                        Prospective     MCPHR
  Pettinari[58](#jah32844-bib-0058){ref-type="ref"}      2015   Ziekenhuis Oost Limburg, Genk, Belgium and University Hospitals Leuven, Leuven, Belgium                        1972--2006     Isolated CABG in patients ≥70 years old              Retrospective   PSM
  Pick[59](#jah32844-bib-0059){ref-type="ref"}           1997   Mayo Clinic, Rochester, MN, USA                                                                                1983--1986     Isolated CABG                                        Retrospective   MCPHR
  Rosenblum[60](#jah32844-bib-0060){ref-type="ref"}      2016   Emory University School of Medicine, Atlanta, GA, USA                                                          2003--2013     Isolated primary CABG                                Retrospective   PSM
  Schwann[61](#jah32844-bib-0061){ref-type="ref"}        2016   Multicenter                                                                                                    1987--2011     Isolated CABG                                        Retrospective   PSM
  Stevens[62](#jah32844-bib-0062){ref-type="ref"}        2004   Montreal Heart Institute, Montreal, Quebec, Canada                                                             1985--1995     Isolated primary CABG                                Retrospective   MCPHR including PS
  Tarelli[63](#jah32844-bib-0063){ref-type="ref"}        2001   Varese Hospital, Varese, Italy                                                                                 1988--1990     Isolated CABG                                        Retrospective   NA
  Toumpoulis[64](#jah32844-bib-0064){ref-type="ref"}     2006   St. Luke\'s--Roosevelt Hospital Center at Columbia University, NY, USA                                         1992--2002     Isolated CABG in diabetic patients                   Retrospective   MCPHR in PS‐matched patients

CABG indicates coronary artery bypass grafting; MCPHR, multivariable Cox proportional hazards regression; NA, not applicable; NR, not reported; NS, not specified; OPCAB, off‐pump coronary artery bypass; PS, propensity score; PSM, propensity‐score matching.

###### 

Overview of the Studies Included in the Primary Analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                  Overall Population, n   UNM BITA, n       UNM SITA, n      PSM BITA, n   PSM SITA, n   Mean/Median Follow‐up (Y)            Completeness of Follow‐up
  ------------------------------------------------------ ----------------------- ----------------- ---------------- ------------- ------------- ------------------------------------ ---------------------------
  Ashraf[27](#jah32844-bib-0027){ref-type="ref"}         300                     150               150              NA            NA            Median (IQR) BITA: 1.9 (1.3--2.6)\   NR
                                                                                                                                                Median (IQR) SITA: 2.3 (1.7--3)      

  Benedetto[28](#jah32844-bib-0028){ref-type="ref"}      4195                    750               3445             750           750           4.8±3.2 (PSM sample)                 100%

  Berreklouw[29](#jah32844-bib-0029){ref-type="ref"}     482                     NA                NA               249           233           BITA: 9.7±2.7\                       94%
                                                                                                                                                SITA: 10.1±2.4                       

  Bonacchi[30](#jah32844-bib-0030){ref-type="ref"}       652                     NA                NA               320           332           5.6±1.4                              99.7%

  Buxton[31](#jah32844-bib-0031){ref-type="ref"}         2853                    1296              1557             NA            NA            4.3                                  95.9%

  Calafiore[32](#jah32844-bib-0032){ref-type="ref"}      1602                    1026              576              570           570           Overall: 7.3±4.8\                    100%
                                                                                                                                                BITA: 7.1±5.0\                       
                                                                                                                                                SITA: 7.5±4.7                        

  Carrier[33](#jah32844-bib-0033){ref-type="ref"}        6655                    Statin+: 1166\    Statin+: 4835\   NA            NA            10                                   99%
                                                                                 Statin−: 69       Statin−: 585                                                                      

  Dalén[34](#jah32844-bib-0034){ref-type="ref"}          49 702                  559               49 143           558           558           7.5                                  100%

  Danzer[35](#jah32844-bib-0035){ref-type="ref"}         521                     382               139              NA            NA            10                                   97.5%

  Dewar[36](#jah32844-bib-0036){ref-type="ref"}          1142                    377               765              NA            NA            4                                    NR

  Endo[37](#jah32844-bib-0037){ref-type="ref"}           1131                    443               688              NA            NA            6.2                                  99.3%

  Gansera 2004[38](#jah32844-bib-0038){ref-type="ref"}   1378                    716               662              NA            NA            5.3                                  NR

  Gansera 2017[39](#jah32844-bib-0039){ref-type="ref"}   250                     NA                NA               125           125           9.3±3.5                              100%

  Grau[40](#jah32844-bib-0040){ref-type="ref"}           6666                    1544              5122             1006          1006          Overall: 10.5±5\                     100%
                                                                                                                                                BITA: 10.9±5\                        
                                                                                                                                                SITA: 10.1±5                         

  Hirotani[41](#jah32844-bib-0041){ref-type="ref"}       303                     179               124              NA            NA            NR                                   95%

  Itoh[42](#jah32844-bib-0042){ref-type="ref"}           400                     107               293              98            196           9.0±5.8                              95.6%

  Johnson[43](#jah32844-bib-0043){ref-type="ref"}        2014                    576               1438             NA            NA            NR                                   100%

  Jones[44](#jah32844-bib-0044){ref-type="ref"}          510                     172               338              NA            NA            5.0±3.1                              100%

  Joo[45](#jah32844-bib-0045){ref-type="ref"}            1749                    392               1357             366           366           Overall: 7.0±2.0\                    98.1%
                                                                                                                                                BITA: 6.9±2.1\                       
                                                                                                                                                SITA: 7.1±2.7                        

  Kelly[46](#jah32844-bib-0046){ref-type="ref"}          7633                    1079              6554             NA            NA            BITA: 5.4\                           NR
                                                                                                                                                SITA: 4.6                            

  Kieser[47](#jah32844-bib-0047){ref-type="ref"}         5067                    1038              4029             NA            NA            Overall: 7\                          NR
                                                                                                                                                BITA: 6.4±3.2\                       
                                                                                                                                                SITA: 7.1±3.4                        

  Kinoshita[48](#jah32844-bib-0048){ref-type="ref"}      1203                    750               453              412           412           PSM BITA: 5.6±3.3\                   99%
                                                                                                                                                PSM SITA: 4.9±3.2                    

  Kurlansky[49](#jah32844-bib-0049){ref-type="ref"}      4584                    2215              2369             Quintiles     Quintiles     Overall: 11.5\                       BITA=96.7%\
                                                                                                                                                BITA: 12.7\                          SITA=98.3%
                                                                                                                                                SITA: 11.1                           

  Locker[50](#jah32844-bib-0050){ref-type="ref"}         8295                    BITA only: 271\   7435             NR            NR            7.6±4.6                              100%
                                                                                 BITA/SVG: 589                                                                                       

  Lytle[51](#jah32844-bib-0051){ref-type="ref"}          10 124                  2001              8123             1152          1152          BITA: 16.2±2.4\                      100%
                                                                                                                                                SITA: 16.3±2.5                       

  Medalion[52](#jah32844-bib-0052){ref-type="ref"}       1627                    1045              582              NA            NA            8.2±4.5                              98%

  Mohammadi[53](#jah32844-bib-0053){ref-type="ref"}      1795                    129               1666             111           111           Overall PSM: 8.0±5.3\                92.7%
                                                                                                                                                PSM BITA: 8.6±5.1\                   
                                                                                                                                                PSM SITA: 7.7±5.5                    

  Nasso[54](#jah32844-bib-0054){ref-type="ref"}          8054                    4088              3966             3584          3584          3.1                                  98%

  Naunheim[55](#jah32844-bib-0055){ref-type="ref"}       365                     100               265              100           100           NR                                   96.5%

  Navia[56](#jah32844-bib-0056){ref-type="ref"}          2486                    2098              388              485           NR            Median: 5.5 (IQR: 2.6--8.8)          95%

  Parsa[57](#jah32844-bib-0057){ref-type="ref"}          17 609                  728               16 881           NA            NA            NR                                   100%

  Pettinari[58](#jah32844-bib-0058){ref-type="ref"}      3496                    1328              2168             892           892           3.1                                  100%

  Pick[59](#jah32844-bib-0059){ref-type="ref"}           321                     NA                NA               160           161           9.8±2.8                              100%

  Rosenblum[60](#jah32844-bib-0060){ref-type="ref"}      8254                    873               7381             306           306           Median: 2.8 (IQR: 1.1--4.9)          100%

  Schwann[61](#jah32844-bib-0061){ref-type="ref"}        5125                    641               4484             551           551           NR                                   100%

  Stevens[62](#jah32844-bib-0062){ref-type="ref"}        4382                    1835              2547             NA            NA            Overall: 11±3\                       98%
                                                                                                                                                BITA: 8±2\                           
                                                                                                                                                SITA: 12±3                           

  Tarelli[63](#jah32844-bib-0063){ref-type="ref"}        300                     150               150              NA            NA            Overall: 9.2\                        100%
                                                                                                                                                BITA: 9.2±2.8\                       
                                                                                                                                                SITA: 9.1±2.5                        

  Toumpoulis[64](#jah32844-bib-0064){ref-type="ref"}     980                     NA                NA               490           490           4.7±3.0                              99.1%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BITA indicates bilateral internal thoracic arteries; IQR, interquartile range; NA, not applicable; NR, not reported; PSM, propensity‐score matched; SITA, single internal thoracic artery; SVG, saphenous vein graft.

The selected studies reported on 174 205 patients (BITA: 32 206; SITA: 141 999) for final comparisons.

Overall, the BITA and SITA groups presented different preoperative risk‐factor distribution (mean age, BITA versus SITA: 60 versus 64.1 years; female sex, BITA versus SITA: 16% versus 20.8%; diabetes mellitus, BITA versus SITA: 32.2% versus 40.5%; chronic obstructive pulmonary disease, BITA versus SITA: 9.6% versus 11.8%; Table [S2](#jah32844-sup-0001){ref-type="supplementary-material"}).

Long‐Term All‐Cause Mortality {#jah32844-sec-0017}
-----------------------------

Mean follow‐up time across the 38 studies was 7.25 years (range, 2.1--16.3). The overall mortality rate at the end of follow‐up was 28.03±18.4% in the BITA versus 39.96±23.5% in the SITA series.

Use of BITA was associated with a statistically significant reduction of mortality at the end of follow‐up when compared with SITA (IRR, 0.74; 95% CI, 0.69--0.80; *P*\<0.001; I^2^=71%; Figure [1](#jah32844-fig-0001){ref-type="fig"}A[27](#jah32844-bib-0027){ref-type="ref"}, [28](#jah32844-bib-0028){ref-type="ref"}, [29](#jah32844-bib-0029){ref-type="ref"}, [30](#jah32844-bib-0030){ref-type="ref"}, [31](#jah32844-bib-0031){ref-type="ref"}, [32](#jah32844-bib-0032){ref-type="ref"}, [33](#jah32844-bib-0033){ref-type="ref"}, [34](#jah32844-bib-0034){ref-type="ref"}, [35](#jah32844-bib-0035){ref-type="ref"}, [36](#jah32844-bib-0036){ref-type="ref"}, [37](#jah32844-bib-0037){ref-type="ref"}, [38](#jah32844-bib-0038){ref-type="ref"}, [39](#jah32844-bib-0039){ref-type="ref"}, [40](#jah32844-bib-0040){ref-type="ref"}, [41](#jah32844-bib-0041){ref-type="ref"}, [42](#jah32844-bib-0042){ref-type="ref"}, [43](#jah32844-bib-0043){ref-type="ref"}, [44](#jah32844-bib-0044){ref-type="ref"}, [45](#jah32844-bib-0045){ref-type="ref"}, [46](#jah32844-bib-0046){ref-type="ref"}, [47](#jah32844-bib-0047){ref-type="ref"}, [48](#jah32844-bib-0048){ref-type="ref"}, [49](#jah32844-bib-0049){ref-type="ref"}, [50](#jah32844-bib-0050){ref-type="ref"}, [51](#jah32844-bib-0051){ref-type="ref"}, [52](#jah32844-bib-0052){ref-type="ref"}, [53](#jah32844-bib-0053){ref-type="ref"}, [54](#jah32844-bib-0054){ref-type="ref"}, [55](#jah32844-bib-0055){ref-type="ref"}, [56](#jah32844-bib-0056){ref-type="ref"}, [57](#jah32844-bib-0057){ref-type="ref"}, [58](#jah32844-bib-0058){ref-type="ref"}, [59](#jah32844-bib-0059){ref-type="ref"}, [60](#jah32844-bib-0060){ref-type="ref"}, [61](#jah32844-bib-0061){ref-type="ref"}, [62](#jah32844-bib-0062){ref-type="ref"}, [63](#jah32844-bib-0063){ref-type="ref"}, [64](#jah32844-bib-0064){ref-type="ref"} and Figure [S2](#jah32844-sup-0001){ref-type="supplementary-material"}). This finding was consistent across the general population and all the specific patient subgroups and all the study designs (Figures [S3 through S5](#jah32844-sup-0001){ref-type="supplementary-material"}) and was not influenced by age, sex, diabetes mellitus, and ejection fraction (Figure [2](#jah32844-fig-0002){ref-type="fig"}).

![A, Forest plot comparing the effect of the use of BITA vs SITA on end of follow‐up mortality across all the included studies (38 studies; 174 205 patients). B, Cumulative analysis of all the included studies using random‐effect model (38 studies; 174 205 patients). BITA indicates bilateral internal thoracic artery; CI, confidence interval; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.](JAH3-7-e008010-g001){#jah32844-fig-0001}

![Results of the metaregression analyses. Univariate metaregression analysis showed that the effect of BITA was not influenced by age (slope *P* value=0.625; intercept *P* value=0.941), sex (slope *P* value=0.160; intercept *P* value=0.0002), diabetes mellitus (slope *P* value=0.730; intercept *P* value=0.0001), and ejection fraction (slope *P* value=0.674; intercept *P* value=0.482). Similarly, multivariate metaregression analysis showed that the effect of BITA was not influenced by age (slope *P* value=0.270), sex (slope *P* value=0.412), diabetes mellitus (slope *P* value=0.848), and ejection fraction (slope *P* value=0.644) with intercept *P* value=0.487 (plot not shown). BITA indicates bilateral internal thoracic artery; DM, diabetes mellitus; EF, ejection fraction.](JAH3-7-e008010-g002){#jah32844-fig-0002}

One‐Year All‐Cause Mortality in the PSM Populations {#jah32844-sec-0018}
---------------------------------------------------

Mean follow‐up time of the 12 PSM studies was 7.41±4.4 years, and the number of patients included was 34 019. Use of BITA was associated with a similar reduction of mortality at 1‐year and at the end of follow‐up (IRR, 0.70; 95% CI, 0.60--0.82 at 1 year versus IRR, 0.77; 95% CI, 0.70--0.85 at the end of follow‐up; *P* for subgroup differences=0.43; Figure [3](#jah32844-fig-0003){ref-type="fig"})[1](#jah32844-note-1002){ref-type="fn"} (details of the statistical analysis for the PSM studies included in this analysis are summarized in Table [S3](#jah32844-sup-0001){ref-type="supplementary-material"}). These findings were robust in a leave‐one‐out analysis (Figure [4](#jah32844-fig-0004){ref-type="fig"}).[2](#jah32844-note-1003){ref-type="fn"}

![Forest plot comparing the effect of the use of BITA vs SITA on end of follow‐up (top) and 1‐year (bottom) mortality in PSM studies in the general population (12 studies; 34 019 patients). BITA indicates bilateral internal thoracic artery; CI, confidence interval; PSM, propensity‐score matched; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.](JAH3-7-e008010-g003){#jah32844-fig-0003}

![Leave‐one‐out analyisis for 1‐year mortality among PSM studies (12 studies). BITA indicates bilateral internal thoracic artery; CI, confidence interval; PSM, propensity‐score matched; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.](JAH3-7-e008010-g004){#jah32844-fig-0004}

Publication Bias and Internal Validity Appraisal {#jah32844-sec-0019}
------------------------------------------------

Study quality was high across all studies included in the primary analysis (Table [S4](#jah32844-sup-0001){ref-type="supplementary-material"}). Overall heterogeneity was high both at 1‐year analysis in the PSM studies (I^2^=51%) and at end of follow‐up in the overall studies analysis (I^2^=71%). Publication bias was low, as assessed by funnel plots, for all‐cause mortality in the primary analysis (Figure [5](#jah32844-fig-0005){ref-type="fig"}).

![Publication bias as assessed by funnel plots for all‐cause mortality in the primary analysis. A, All included studies. B, Studies performed in the general population vs studies performed in specific subpopulations. C, Unadjusted studies vs adjusted studies. D, PSM studies vs adjusted non‐PSM studies. E, PSM studies at 1‐year follow‐up vs PSM studies at end of follow‐up. PSM indicates propensity‐score matched.](JAH3-7-e008010-g005){#jah32844-fig-0005}

An overview of the results of all the analyses is provided in Table [S5](#jah32844-sup-0001){ref-type="supplementary-material"}.

Discussion {#jah32844-sec-0020}
==========

For almost 25 years, the concept that the use of BITA is associated with improved survival after coronary artery bypass surgery has been accepted in the cardiovascular community. This concept is almost completely based on observational studies.

To date, at least 60 English‐language observational studies comparing the clinical outcome of BITA and SITA patients have been published (Figure [S1](#jah32844-sup-0001){ref-type="supplementary-material"}). The overwhelming majority of these have shown better outcomes in the BITA treatment group. Several reports have also suggested that the advantages of BITA grafting could be extended to females,[65](#jah32844-bib-0065){ref-type="ref"} diabetics,[66](#jah32844-bib-0066){ref-type="ref"} and patients with chronic renal insufficiency.[48](#jah32844-bib-0048){ref-type="ref"} Over time, this evidence has been summarized in 6 meta‐analyses.[4](#jah32844-bib-0004){ref-type="ref"}, [5](#jah32844-bib-0005){ref-type="ref"}, [6](#jah32844-bib-0006){ref-type="ref"}, [7](#jah32844-bib-0007){ref-type="ref"}, [8](#jah32844-bib-0008){ref-type="ref"}, [9](#jah32844-bib-0009){ref-type="ref"} All of them showed a significant and similar survival advantage, as measured by the HR, for the use of BITA (see Table [3](#jah32844-tbl-0003){ref-type="table-wrap"}).[4](#jah32844-bib-0004){ref-type="ref"}, [5](#jah32844-bib-0005){ref-type="ref"}, [6](#jah32844-bib-0006){ref-type="ref"}, [7](#jah32844-bib-0007){ref-type="ref"}, [8](#jah32844-bib-0008){ref-type="ref"}, [9](#jah32844-bib-0009){ref-type="ref"}

###### 

Published Meta‐Analyses of the Observational Evidence on the BITA vs SITA Comparison

  First Author, Year                                     Studies Included in Survival Analysis, n   Patients Included in Survival Analysis, n   Type of Observational Studies Included   Patient Populations Excluded by Inclusion Criteria   HR in Favor of BITA
  ------------------------------------------------------ ------------------------------------------ ------------------------------------------- ---------------------------------------- ---------------------------------------------------- ----------------------------
  Taggart, 2001[5](#jah32844-bib-0005){ref-type="ref"}   7                                          15 962                                      All                                      None                                                 0.81 \[95% CI 0.70--0.94\]
  Rizzoli, 2002[4](#jah32844-bib-0004){ref-type="ref"}   7                                          15 299                                      All                                      High‐risk patients, emergencies, diabetics           0.79 \[95% CI 0.66--0.91\]
  Weiss, 2013[7](#jah32844-bib-0007){ref-type="ref"}     27                                         79 063                                      All                                      None                                                 0.78 \[95% CI 0.72--0.84\]
  Takagi, 2014[6](#jah32844-bib-0006){ref-type="ref"}    20                                         70 897                                      Adjusted                                 None                                                 0.80 \[95% CI 0.77--0.84\]
  Yi, 2014[8](#jah32844-bib-0008){ref-type="ref"}        9                                          15 583                                      Adjusted                                 None                                                 0.79 \[95% CI 0.75--0.84\]
  Buttar, 2017[9](#jah32844-bib-0009){ref-type="ref"}    29                                         89 399                                      All                                      None                                                 0.78 \[95% CI 0.72--0.84\]

BITA indicates bilateral internal thoracic artery; HR, hazard ratio; PSM, propensity‐score matched; UNM, unmatched.

Our analysis pools data from 38 of these studies and 174 205 patients and confirms the previous findings (Table [3](#jah32844-tbl-0003){ref-type="table-wrap"}).[4](#jah32844-bib-0004){ref-type="ref"}, [5](#jah32844-bib-0005){ref-type="ref"}, [6](#jah32844-bib-0006){ref-type="ref"}, [7](#jah32844-bib-0007){ref-type="ref"}, [8](#jah32844-bib-0008){ref-type="ref"}, [9](#jah32844-bib-0009){ref-type="ref"} We used IRRs instead of HR or relative risk ratio to account for potential differences in follow‐up duration within studies and between studies. We confirmed better long‐term survival for BITA compared with SITA (IRR, 0.74; 95% CI, 0.69--0.80; *P*\<0.001; Figure [1](#jah32844-fig-0001){ref-type="fig"}A).^27--64^ This difference was evident independently from the patient population included and the methodology used ([Figures S3 through S5](#jah32844-sup-0001){ref-type="supplementary-material"}). The benefit was uncertain from 1989 to 2000, was consistently significant at the 0.05 level starting in 2001, and crossed the 0.01 and 0.001 levels in 2004 (Figure [1](#jah32844-fig-0001){ref-type="fig"}B).[27](#jah32844-bib-0027){ref-type="ref"}, [28](#jah32844-bib-0028){ref-type="ref"}, [29](#jah32844-bib-0029){ref-type="ref"}, [30](#jah32844-bib-0030){ref-type="ref"}, [31](#jah32844-bib-0031){ref-type="ref"}, [32](#jah32844-bib-0032){ref-type="ref"}, [33](#jah32844-bib-0033){ref-type="ref"}, [34](#jah32844-bib-0034){ref-type="ref"}, [35](#jah32844-bib-0035){ref-type="ref"}, [36](#jah32844-bib-0036){ref-type="ref"}, [37](#jah32844-bib-0037){ref-type="ref"}, [38](#jah32844-bib-0038){ref-type="ref"}, [39](#jah32844-bib-0039){ref-type="ref"}, [40](#jah32844-bib-0040){ref-type="ref"}, [41](#jah32844-bib-0041){ref-type="ref"}, [42](#jah32844-bib-0042){ref-type="ref"}, [43](#jah32844-bib-0043){ref-type="ref"}, [44](#jah32844-bib-0044){ref-type="ref"}, [45](#jah32844-bib-0045){ref-type="ref"}, [46](#jah32844-bib-0046){ref-type="ref"}, [47](#jah32844-bib-0047){ref-type="ref"}, [48](#jah32844-bib-0048){ref-type="ref"}, [49](#jah32844-bib-0049){ref-type="ref"}, [50](#jah32844-bib-0050){ref-type="ref"}, [51](#jah32844-bib-0051){ref-type="ref"}, [52](#jah32844-bib-0052){ref-type="ref"}, [53](#jah32844-bib-0053){ref-type="ref"}, [54](#jah32844-bib-0054){ref-type="ref"}, [55](#jah32844-bib-0055){ref-type="ref"}, [56](#jah32844-bib-0056){ref-type="ref"}, [57](#jah32844-bib-0057){ref-type="ref"}, [58](#jah32844-bib-0058){ref-type="ref"}, [59](#jah32844-bib-0059){ref-type="ref"}, [60](#jah32844-bib-0060){ref-type="ref"}, [61](#jah32844-bib-0061){ref-type="ref"}, [62](#jah32844-bib-0062){ref-type="ref"}, [63](#jah32844-bib-0063){ref-type="ref"}, [64](#jah32844-bib-0064){ref-type="ref"}

Basing on these data, the current US[10](#jah32844-bib-0010){ref-type="ref"} and European[11](#jah32844-bib-0011){ref-type="ref"} Guidelines encourage the use of a second arterial graft in patients with a long life expectancy, and last year the Society of Thoracic Surgeons published a position paper strongly encouraging a wider use of arterial grafts.[12](#jah32844-bib-0012){ref-type="ref"}

It must, however, be noted that the results of the observational studies have not been confirmed in the randomized comparisons. The 4 RCTs that have compared BITA and SITA to date have all failed to show a survival difference between the 2 revascularization strategies.[13](#jah32844-bib-0013){ref-type="ref"}, [14](#jah32844-bib-0014){ref-type="ref"}, [15](#jah32844-bib-0015){ref-type="ref"}, [16](#jah32844-bib-0016){ref-type="ref"} Two of the RCTs were small, with less than 100 patients in each arm, and had limited follow‐up, so that they were probably underpowered to detect moderate differences.[13](#jah32844-bib-0013){ref-type="ref"}, [14](#jah32844-bib-0014){ref-type="ref"} Another study was moderate in size (Stand‐in‐Y,[15](#jah32844-bib-0015){ref-type="ref"} 800 patients) and the most recent, the ART trial,[16](#jah32844-bib-0016){ref-type="ref"} included more than 3000 patients.

The Stand‐in‐Y Mammary study compared the outcomes of 800 patients randomized to receive BITA using 2 different configurations: SITA and radial artery or SITA and saphenous vein.[15](#jah32844-bib-0015){ref-type="ref"} At a mean follow‐up of 24.1±9.8 months, no difference in survival was found between the BITA and SITA groups (*P*=0.62; odds ratio, 0.63; 95% CI, 0.27--1.47), although patients with arterial grafts had better cardiac event--free survival (Wilcoxon test, *P*\<0.0001).

The ART trial randomized 3102 patients to receive 1 or 2 internal thoracic arteries.[16](#jah32844-bib-0016){ref-type="ref"} The primary end point is overall survival, and the study was designed to be able to detect a 20% reduction in the primary end point at 10 years. At a planned 5‐year interim analysis, no difference in survival (91.3% in the BITA group and 91.6% in the SITA group; HR, 1.04; CI, 0.81--1.32) or in the composite of mortality, myocardial infarction, and/or stroke (12.2% BITA versus 12.7% SITA; HR, 0.96; CI, 0.79--1.17) was found between groups.

Several methodological flaws in the design of the RCTs can partially explain the variance between the results of the randomized and observational studies. All the RCTs were limited to mid‐term follow‐up, and it is known the attrition rate of saphenous grafts remains low at 5 years[19](#jah32844-bib-0019){ref-type="ref"}; it is possible that a difference between the groups would have become apparent with further follow‐up. There are additional considerations specifically regarding the ART study that may explain a negative result. A sizeable proportion (23%) of patients randomized to SITA also received a radial artery as an additional arterial graft. There was a high rate of crossover in the group allocated to BITA (16.4%). There was very high compliance with optimal medical therapy in both groups (90% of patients on aspirin, beta‐blockers, and statins). Finally, there was a treatment age interaction that approached statistical significance, favoring BITA in patients aged \<70 years whereas BITA appeared harmful in patients aged \>70.

There are, however, biological reasons in support of the results of the RCTs. A second arterial conduit to a non‐LAD target has less potential to impact on overall survival than the single left internal thoracic artery to the LAD. Solid evidence suggests, in fact, that in coronary artery bypass surgery, patient survival is mainly determined by the status of the LAD and that grafts to non‐LAD vessels are more likely to affect other cardiac end points (myocardial infarction, angina recurrence, and need for revascularization), but not overall survival.[27](#jah32844-bib-0027){ref-type="ref"}, [28](#jah32844-bib-0028){ref-type="ref"}, [29](#jah32844-bib-0029){ref-type="ref"} The LAD also can provide collaterals to other coronaries (commonly the right coronary); a persistently patent internal thoracic artery graft to the LAD can therefore supply not only the anterior wall, but, through collaterals, viable myocardium in other territories. Last, patency of grafts to the LAD generally exceed the patency of grafts to non‐LAD vessels.[3](#jah32844-bib-0003){ref-type="ref"}

Our hypothesis, however, is that the difference in results between the RCTs and the observational evidence is attributed to unmeasured confounders and not to the difference in revascularization strategy.

In order to test this hypothesis, we repeated the BITA versus SITA comparison at 1 year, when the attrition rate of the SVGs is still low and a survival difference attributable to a difference in graft patency is unlikely.

Because PSM studies are considered the observational studies less prone to confounders, we decided to limit the 1‐year analysis to PSM studies only.

In fact, PSM series constitute a large amount of the current evidence in the surgical fields.[20](#jah32844-bib-0020){ref-type="ref"} The PSM process is thought to be able to minimize differences in the preoperative risk profile of the patients, and PSM studies are often quoted as the best level of evidence after RCTs.[20](#jah32844-bib-0020){ref-type="ref"}

We found that the relative survival advantage attributed to the BITA group at 1 year was similar to that observed at late follow‐up (Figure [3](#jah32844-fig-0003){ref-type="fig"}).[3](#jah32844-note-1004){ref-type="fn"}

This finding suggests that factors not related to the conduit patency, such as the patients' general status or quality of the target vessels, played a role in determining the outcome and that unmatched biases are present even in PSM studies.

The use of the BITA increases the complexity and invasiveness of the procedure. It is likely that surgeons tend to reserve this operation for the patients perceived as healthier and with longer life expectancy from a cardiac and a general health perspective. A bias may also exist in terms of the graftability and location of the target vessels. This type of "eye‐balling" or clinical acumen based on the individual surgeon\'s experience is very difficult to quantify; the statistics can only be adjusted for the measured, and not for the unmeasured, confounders. Our findings elicit concerns on the ability of the propensity‐matching process to overcome treatment allocation biases in observational studies and assure comparability between groups.

Limitations {#jah32844-sec-0021}
-----------

This analysis shares the common limitations of meta‐analysis of observational data, although the funnel plots do not indicate important publication bias.

In addition, the different studies included different surgical techniques (on‐ versus off‐pump) and grafting strategies (single versus composite grafts) as well as different definitions and matching algorithms, so that the homogeneity of the included population cannot be regarded as optimal.

In most of the series, the 1‐year IRR was not specified in the original study and had to be derived using the described statistical methods.

Upon careful review of the methods of the PSM studies, we could not confer that the original studies adjusted the variance estimates appropriately for the matched nature of the data in the original studies (Table [S3](#jah32844-sup-0001){ref-type="supplementary-material"}). That said, the HRs would still be correct, and the leave‐one‐out analysis was consistent with the overall findings.

Finally, given that we included only articles in English, a language bias cannot be excluded, although there are no plausible biological reasons to support it.

Conclusions {#jah32844-sec-0022}
===========

In conclusion, the present meta‐analysis challenges the benefit traditionally attributed to BITA grafting. The fact that, even in the PSM series, BITA patients exhibit a significant survival advantage at 1‐year follow‐up suggests that unmeasured confounders may account for the reported survival benefit of BITA in the observational series.

In addition, our results suggest that even our best statistical methods to minimize baseline demographic differences in observational studies have major limitations.

Later reporting of the clinical outcomes of ART and new randomized studies are needed to clarify the effect of BITA grafting in patients undergoing CABG.

Sources of Funding {#jah32844-sec-0023}
==================

Prof Fremes is partially supported by the Bernard S. Goldman Chair in Cardiovascular Surgery.

Disclosures {#jah32844-sec-0024}
===========

Prof Fremes is supported, in part, by the Bernard S. Goldman Chair in Cardiovascular Surgery. The remaining authors have no disclosures to report.

Supporting information
======================

###### 

**Data S1.** Full search strategy.

**Table S1.** Pretreatment Variables Included for Propensity‐Score Matching
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**Figure S2.** Leave‐one‐out analysis for the end of follow‐up mortality among all the studies included in the primary analyisis (38 studies). Incident rate ratio (IRR) is used.

**Figure S3.** Forest plots comparing the effect of the use of BITA vs SITA on end of follow‐up mortality after the exclusion of studies performed in specific subpopulations (28 studies; 162 989 patients, top) and in those studies performed in specific subpopulations (10 studies; 11 216 patients, bottom). BITA indicates bilateral internal thoracic artery; CI, confidence interval; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.

**Figure S4.** Forest plots comparing the effect of the use of BITA vs SITA on end of follow‐up mortality in adjusted (22 studies; 155, 925 patients, top) and unadjusted (6 studies; 7064 patients, bottom) studies in the general population. BITA indicates bilateral internal thoracic artery; CI, confidence interval; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.

**Figure S5.** Forest plots comparing the effect of the use of BITA vs SITA on end of follow‐up mortality in adjusted non‐PSM studies (10 studies; 43 855 patients, top) and PSM studies (12 studies; 34 019 patients, bottom) in the general population. BITA indicates bilateral internal thoracic artery; CI, confidence interval; PSM, propensity‐score matched; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.
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